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HIV-1 Nef protein has key roles at almost all stages of the viral life cycle. We assessed the role of the Nef/eEF1A (eukaryotic
translationelongationfactor1-alpha)complexinnucleocytoplasmicshuttlinginprimaryhumanmacrophages.Nuclearretention
experiments and inhibition of the exportin-t (Exp-t) pathway suggested that cytoplasmic relocalization of eEF1A, mediated by
Exp-t, occurs in Nef-treated monocyte-derived macrophages (MDMs). We observed the presence of tRNA in the Nef/eEF1A
complexes. Nucleocytoplasmic relocalization of the Nef/eEF1A complexes prevented stress-induced apoptosis of MDMs
treated with brefeldin-A. Blockade of stress-induced apoptosis of MDMs treated with HIV-1 Nef resulted from enhanced
nucleocytoplasmic transport of eEF1A with decreased release of mitochondrial cytochrome c, and from increased tRNA
binding to cytochrome c, ultimately leading to an inhibition of caspase activation. Our results indicate that HIV-1 Nef, through
the nucleocytoplasmic relocalization of eEF1A and tRNAs, enhances resistance to stress-induced apoptosis in primary
human macrophages.
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The endoplasmic reticulum (ER) is a well-orchestrated
protein-folding machine composed of protein chaperones,
proteins that catalyze protein folding, and sensors that detect
the presence of misfolded or unfolded proteins. The unfolded
protein response (UPR) is an intracellular signaling pathway
that coordinates ER protein-folding demand with protein-
folding capacity and is essential to adapt to homeostatic
alterations that cause protein misfolding.
1 Accumulating
evidence suggests that protein folding and generation of
reactive oxygen species (ROS) as a byproduct of protein
oxidation in the ER are closely linked events. It has also
become apparent that activation of the UPR on exposure to
oxidative stress is an adaptive mechanism to preserve cell
function and survival.
1 Persistent oxidative stress and protein
misfolding initiate apoptotic cascades and are now known to
havepredominantrolesinthepathogenesisofmultiplehuman
diseases, including diabetes, atherosclerosis and neurode-
generative diseases.
2
Excessive ROS production not appropriately compensated
by antioxidant molecules can lead to oxidative stress, which
may have an important role in pathogenesis of HIV infection
throughvarious mechanisms.
3–5 Inmonocytes from asympto-
matic patients, the levels of Bcl-2 and thioredoxin (TRX)
decrease,
4 which is associated with enhanced hydrogen
peroxide production, whereas in cells from AIDS patients the
levels returned to normal.
6 Thus, the redox balance affected
by the intracellular TRX system seems to be important for cell
survival and low viral production, probably leading to chronic
persistent infection of HIV. HIV-1 Tat has been reported to
induce UPR,
7 indicating that ER stress response could be a
critical parameter to control during HIV infection.
The translation elongation factor EF1A has been described
as a cytoplasmic component of the nuclear aminoacylation-
dependent tRNA export pathway.
8 Eukaryotic translation
elongation factor 1-alpha (eEF1A) interacts directly with
aminoacylated tRNAs. Exportin-t (Exp-t) has been reported
to have a major role in eEF1A-mediated export, although
Exp-5, which preferentially exports pre-miRNAs, has been
reported to be involved in the nuclear-cytoplasmic transport
of tRNAs in some cases.
9 In addition to the conventional role
of eEF1A during protein synthesis, namely GTP-dependent
binding and transport of aminoacyl-tRNA to the A site of the
ribosome, eEF1A has a role in the cytoplasm. One of the
proposed unconventional functions of eEF1A is a role in the
regulation of cytoskeletal dynamics.
10 In addition to binding
GDP/GTP, aminoacyl-tRNA, EF1b and the ribosome, eEF1A
binds and bundles actin and binds to microtubules. Because
eEF1A is an abundant protein in most eukaryotic cells and
binds to actin ﬁlaments with relatively high afﬁnity, it could be
a potent regulator of the cytoskeleton.
11 Previous in vitro
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polymerization and stabilizes actin ﬁlaments.
12
In addition, eEF1A has been reported to have a role in
apoptosis or programmed cell death. Early experiments
showed that the level of eEF1A expression in cultured mouse
ﬁbroblasts correlates with the rate of apoptosis on serum
withdrawal, with higher levels of eEF1A expression asso-
ciated with a faster rate of cell death.
13 Other studies have
indicated that eEF1A prevents cell death, and numerous
studies have shown that eEF1A expression increases in
tumor cells and tumor tissues parallel with decreased
caspase-3 activation.
14,15
Nef a 27-kDa HIV-1 protein is translated from multiply
spliced viral mRNAs early during infection.
16 Endogenous Nef
may have evolved a number of different, independent
functional activities to enhance the replication and survival
of the virus within infected cells and to facilitate its spread
in vivo.
17 Nef enhances virion infectivity and increases viral
replication in primary lymphocytes and macrophages.
18 The
protein can also mediate downregulation of CD4 cell surface
expression, a phenomenon important for the release of HIV-1
from the cell.
17 In addition, Nef can downregulate the cell
surface expression of major histocompatibility complex class I
molecules, an effect found to protect infected cells from
cytotoxic T cells.
19 The Nef protein prevents apoptosis of HIV-
1-infected T cells through either interference with Fas/TNFa
receptor death signaling pathways by inhibiting apoptosis
signal-regulating-kinase 1 (ASK-1)
20 or the formation of a
complex with both p21-activated kinase and phosphatidylino-
sitol-3-kinase, which increases phosphorylation and inactiva-
tion of the proapoptotic Bad protein.
21 HIV-1 Nef protects
human monocyte-derived macrophages (MDMs) from HIV-1-
induced apoptosis, and this protection correlates with the
hyperphosphorylation and consequent inactivation of Bad.
22
Nef expression within macrophages has been reported to
favortherecruitmentofrestingTcellsviathesecretionofC–C
chemokines and to subsequently favor their activation,
suggesting a role for Nef in lymphocyte recruitment and
activation at sites of viral replication.
23
Our results indicate that HIV-1 Nef associates with
eEF1A and that Exp-t contributes to the nuclear-cytoplasmic
transport of Nef/eEF1A/tRNA complexes in macrophages.
Finally, we observed that cytoplasmic relocalization of the
Nef/eEF1A/tRNA complexes prevents stress-induced apop-
tosis in macrophages via increased cytoplasmic eEF1A
expression, decreased release of mitochondrial cytochrome
c and plugging of released cytochrome c by cytoplasmic
tRNAs, ultimately resulting in decreased caspase activation.
Results
Identiﬁcation of the interaction between HIV-1 Nef and
eEF1A. In order to identify potential HIV-1 Nef protein/
protein interactions, we screened high-density protein
expression ﬁlter membranes containing 55296 clones from
a human fetal brain library using Far-western analysis with
recombinant HIV-1 Nef as bait.
24 We identiﬁed eEF1A as a
potential binding candidate (Figure 1a). To test this interac-
tion, we expressed a Nef–GST (glutathione S-transferase)
fusion protein in E. coli and tested its ability to interact with
eEF1A from U937 cell lysates. The Nef protein bound to
eEF1A (Figure 1b). Endogenous eEF1A protein present in
the lysates of Vero cells, MRC5 cells, promonocytic U937
cells, primary peripheral blood lymphocytes (PBLs) and
primary MDMs co-immunoprecipitated with recombinant
Nef (rNef) added to the culture, whereas the isotype control
showed no associated eEF1A protein on immunopreci-
pitation (Figure 1c). Although the interaction between eEF1A
and rNef was detected in both nuclear and cytoplasmic
lysates prepared from the cell lines (Vero cells, MRC5 cells,
U937 cells), we measured more eEF1A/rNef complexes in
the nucleus than in the cytoplasm of primary MDMs and
PBLs early post-treatment (30min; Figure 1c).
The interaction between eEF1A and endogenous Nef was
also demonstrated by transient transfection of U937 cells with
a nef-expressing plasmid (Figure 1d), and in peripheral blood
mononuclear cells (PBMCs) infected in vitro with HIV-189.6
(Figure 1e). Thus, eEF1A interacts with the Nef protein, not
only in vitro within several cell types treated with rNef, but also
with the endogenous Nef protein produced within HIV-1-
infected primary PBMCs. Lysates from MDMs treated with
Figure 1 eEF1A interacts with HIV-1 Nef protein in vitro and in vivo.( a) Image analysis of a high-density protein ﬁlter array screened by nonradioactive Far-western
blottingusingHIV-189.6Nefasaprobe.Amagniﬁedsectionoftheblotisshown,indicatingtheinteractingdouble-spottedeEF1Aclones(black).Guidedots(white)onthehigh-
densityﬁlter membranefacilitateidentiﬁcation of thexy-coordinatesof positiveclones.(b) Bindingof HIV-1Nef to eEF1Awas measuredin GSTpull-downassaysusingU937
cells as a source of lysates. Input corresponds to 10% of the material used for pull-down. b-Actin detection represents input loading controls of the lystates that were used in
binding reactions. Results are representative of three independent experiments. The right panel represents Commassie staining of expressed proteins that were used in the
binding reaction of GST pull-down. (c) Cytoplasmic and nuclear extracts from several cell lines (Vero, MRC5, U937 cells), PBLs, and MDMs treated with rNef (100ng/ml) for
0.5h were immunoprecipitated with an anti-eEF1A antibody, or Nef (100ng/ml)-treated total cellular lysates were immunoprecipitated with an isotype control antibody.
Immunoprecipitated material was analyzed by western blotting with an anti-Nef monoclonal antibody. Recombinant Nef-treated total cell lysates were used as a positive
control. Results are representative of three independent experiments. (d) Cellular extracts of MDMs transfected for 48h with a nef-expressing plasmid (pNef) were
immunoprecipitated with an anti-eEF1A antibody, anti-Nef antibody, or isotype control antibody. Immunoprecipitated material was analyzed by western blotting with an anti-
Nef monoclonal antibody. Results are representative of two independent experiments. (e) Cellular extracts of PBMCs infected in vitro with HIV-189.6 or mock infected were
immunoprecipitatedwithan anti-eEF1Aantibodyor anti-Nefmonoclonalantibody.Immunoprecipitatedmaterial wasanalyzedby westernblottingwith an anti-Nefmonoclonal
antibody or anti-eEF1A antibody. Results are representative of two independent experiments. (f and g) eEF1A and HIV-1 Nef interact in vitro in a mammalian two-hybrid
assay.(f)Schematicrepresentationofexpressionconstructsusedinco-transfectionexperimentsinthemammaliantwo-hybridmodel.(g)Mammaliantwo-hybridanalysiswith
eEF1Afusedto theVP16activatordomainand HIV-1Neffusedto theGAL4 domain.Luciferaseassayswereconductedon totalextractsfromU937cells transfectedwith the
luciferase expression construct pG5–Luc, pBIND–Nef, pACT–eEF1A or control plasmids. Results represent the average of a triplicate experiment in which luciferase was
normalized to protein expression. As a positive control, two plasmids, pACT-MyoD and pBIND-Id, were co-transfected, and co-transfection of empty vectors was used as a
negative control. Results represent the mean of three independent experiments. *** Po0.001
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Cell Death and DiseaserNef in vitro were immunoprecipitated with antibodies directed
against eukaryotic translation elongation factor-2 (eEF2), and
western blot performed with an anti-Nef antibody. The Nef
protein did interact with eEF1A, but not with eEF2 (data not
shown), indicating that the Nef/eEF1A interaction was
speciﬁc. We further investigated the interaction between
eEF1A and Nef using a mammalian two-hybrid assay. Nef
fused to the GAL4 DNA-binding domain (pBIND) was used as
the bait vector, and eEF1A fused to the VP16-activation
domain (pACT) was used as the prey vector (Figure 1f). The
constructs were transfected into mammalian cells along with
the pG5Luc vector, which contains ﬁve GAL4 binding sites
upstream of a minimal TATA box upstream of the luciferase
gene. The interaction between the GAL4–Nef and VP16–
eEF1A fusion constructs resulted in an 18-fold increase of
relative luciferase expression over the negative control (1847
versus 105 relative light units (rlu); Figure 1g). Expression of
pGAL4–Nef alone or pVP16–eEF1A alone did not result in
increased luciferase activity compared with negative controls
(115 and 103 rlu, respectively).
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Cell Death and DiseaseDetermination of eEF1A and HIV-1 Nef regions involved
in eEF1A–Nef interaction. To determine the region of
eEF1A responsible for association with HIV-1 Nef, we used
deletion mutants engineered within the cDNA encoding
eEF1A.
25 Lysates from bacteria expressing N-terminal HA-
tagged eEF1A mutants were used in binding reactions with
GST–HIV-1 Nef. The deletion mutants we analyzed are
shown in Figure 2a. Three of the deletion mutants were not
stably expressed (Figure 2a, bacterial expression). Of the
mutants that were expressed, only the eEF1A 1–74 mutant
was capable of binding Nef (Figure 2a). These results
demonstrate that the eEF1A fragment encoding the
N-terminal 74 amino acids is sufﬁcient for HIV-1 Nef binding.
To determine the region of HIV-1 Nef responsible for
binding to eEF1A, two GST–Nef deletion mutants (C
terminus, GST–Nef1-60; N terminus, GST–Nef55-206) were
producedandassayedfortheirabilitytoassociatewitheEF1A
in vitro (Figure 2b). The GST–Nef1-60 and GST–Nef55-206
mutants had intact C-terminal and N-terminal sequences
(data not shown). Lysates from MDMs were used in binding
reactions with GST–HIV-1 Nef constructs. Of the three GST–
Nef constructs, only GST–NefWT and GST–Nef55-206 were
capable of binding eEF1A (Figure 2b). These results
demonstrate that the N terminus of Nef is not required for
eEF1A binding, and that the Nef fragment encoding amino
acids 55 to 206 is sufﬁcient.
Cytoplasmic relocalization of eEF1A by HIV-1 Nef is
mediated by Exp-t. eEF1A protein is found in both the
nucleus and cytoplasm of cells, which favors the nuclear
export of mature tRNAs. In the absence of Nef, we observed
much more eEF1A in the nucleus than the cytoplasm of
primary MDMs (Figure 3a). To determine whether Nef, via its
interaction with eEF1A, interferes with the nuclear-cytoplas-
mic distribution of eEF1A, we treated MDMs with rNef.
26
Nuclear and cytoplasmic extracts were prepared from cells
treated up to 12h with rNef, and the eEF1A/rNef interaction
was assessed in both cellular compartments. Recombinant
Nef enhanced the nuclear-cytoplasmic transport of eEF1A up
to 12h post-treatment in MDMs (Figure 3a). Our results
indicate that rNef could actively favor the nuclear export of
eEF1A in MDMs.
We tested several exportins, Exp-t, Exp-1 and Exp-5, with
regard to the nuclear-cytoplasmic transport of eEF1A in the
presence of rNef. Using MDM lysates, we detected a direct
interaction between GST–Nef and Exp-t using a pull-down
assay (Figure 3b). No direct interaction between GST–Nef
andExp-1wasobserved(datanotshown).Usinglysatesfrom
untreated MDMs, we detected an interaction between eEF1A
and Exp-t by co-immunoprecipitation (Figure 3c). We did not
detect any interaction between eEF1A and Exp-1 in untreated
MDMs (data not shown).
Conﬁrming an interaction between Exp-t and eEF1A or Nef,
we observed a transient rNef/eEF1A/Exp-t complex in
cytoplasmic extracts from MDMs treated with rNef 30min
post-treatment (Figure 3a). A sustained presence of rNef/
eEF1A complexes was detected in the cytoplasm of rNef-
treated MDMs up to 12h post-treatment (Figure 3a). To
determine the role of Exp-t in the nuclear-cytoplasmic
transport of rNef/eEF1A complexes, MDMs were transfected
withExp-t siRNA 48h priortotreatment withrNef.Knockdown
of the Exp-t protein in MDMs was monitored by western blot
(Figure3d).KnockdownofExp-tresultedinenhancednuclear
retentionofeEF1AandrNefinMDMculturestreatedwithrNef
(Figure 3e). We did not detect any nuclear retention of rNef or
eEF1A following treatment of MDMs with the Exp-1 inhibitor
leptomycin B or Exp-5 siRNA (data not shown). Our results
indicate that, in rNef-treated MDMs, the nuclear-cytoplasmic
transport of rNef/eEF1A complexes is preferentially mediated
by Exp-t.
Nuclear-cytoplasmic relocalization of eEF1A by rNef
blocks stress-induced apoptosis in macrophages. Bre-
feldin-A (BFA) disrupts the organization of the microtubule
and actin cytoskeleton and exerts ER and Golgi stress, resulting
in apoptosis (Supplementary Figure 1). Interestingly, eEF1A
is an actin/microtubule binding protein and could interfere
with BFA-induced apoptosis. Therefore, we examined whether
nuclear-cytoplasmic transport of eEF1A by rNef inhibits BFA-
induced apoptosis in MDMs, potentially due to cytoplasmic
accumulation of eEF1A. We observed that pretreatment with
rNef inhibits BFA-induced apoptosis in MDMs in a dose-
dependent manner (Figure 4a). In addition, pretreatment with
rNef did not inhibit apoptosis induced by tunicamycin (TM) or
thapsigargin (TG) that disturb protein glycosylation or Ca
2þ
signaling, respectively (Figure 4b). Of the three Nef proteins,
only NefWT and Nef55–206 were capable of blocking BFA-
induced apoptosis in MDMs (Figure 4c).
Because Exp-t is involved in nuclear-cytoplasmic transpor-
tation of the eEF1A/rNef complexes, we assessed apoptosis
among MDMs treated with rNef prior to BFA treatment and
transfected with siRNA Exp-t, siRNA Exp-1, siRNA Exp-5 or
scramble control. We observed that transfection with siRNA
Exp-t,butnotsiRNA Exp-1orsiRNAExp-5,inhibitedtherNef-
mediated blockade of apoptosis in MDMs treated with BFA
(Figure 4d). Our results indicate that Exp-t-mediated nuclear-
cytoplasmic transport of the rNef/eEF1A complexes in MDMs
is involved in the inhibition of apoptosis triggered by stress,
such as BFA treatment.
As shownin Figure 5a, p35 procaspase-3 is diminished and
cleaved to p20/p17 proteins in MDMs treated with BFA,
conﬁrming that BFA-induced apoptosis activates caspase-
3.
27,28 Under ER stress treatments, such as BFA, the
magnitude of protection against apoptosis directly correlates
with the level of cytoplasmic eEF1A expression
29,30; there-
fore, we measured the levels of eEF1A in the cytosol of BFA-
stimulated MDMs treated with increasing concentrations of
Nef. We observed that the levels of cytosolic eEF1A positively
correlatedwithNeftreatmentinadose-dependentmanner,as
well as with the resistance to apoptosis in BFA-stimulated
MDMs as measured by decreased caspase-3 activation
(Figure 5b).
Cytoplasmic extracts of BFA-stimulated MDMs treated with
rNef,intheabsenceorpresenceofExp-tsiRNA,Exp-1siRNA
or Exp-5 siRNA, were analyzed for caspase-3 activation.
Exp-t, Exp-1 and Exp-5 knockdown in MDMs was monitored
by western blot (Figures 3d and 5c). Knockdown of Exp-t, but
not Exp-1 or Exp-5, relieved the Nef-mediated blockade of
apoptosis in BFA-stimulated MDMs (Figure 5d). Relief of the
Nef-mediatedblockadeofapoptosisinBFA-stimulatedMDMs
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Cell Death and Diseasetransfectedwith Exp-t siRNA was accompanied bydecreased
cytoplasmic eEF1A (Figure 5d). Our results indicate a critical
role for Exp-t and eEF1A in resistance to apoptosis in BFA-
treated MDMs.
Cytochrome c-induced caspase-9 activation is regulated at
multiple levels, and tRNA was reported recently to bind to
cytochrome c, blocking formation of the apoptosome and the
subsequent activation of caspase-9.
31 Therefore, we tested
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Figure 2 TheN-terminal74amino acidsof eEF1Abindsto theC-terminalregion(aa 55–206)ofHIV-1 Nef.(a)TheN-terminalregionis sufﬁcientfor bindingto HIV-1Nef.
Upperpanel,SchematicdiagramofeEF1AmutantsexpressedinbacteriaasHA-taggedfusionproteins.Thenamesofthemutantsareshowntotheleftoftheﬁgure;numbers
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the right of the ﬁgure. NA, not applicable; WT, wild type. Lower panel, eEF1A interacts with HIV-1 Nef via its N terminus extremity (aa 1–74). Using wild-type GST–Nef
constructs, binding of puriﬁed WT eEF1Aand eEF1A1–74 was measured in GSTpull-downassays. Input correspondsto 10%of thematerial used for pull-down. Resultsare
representative of two independent experiments. (b) The C-terminal region (aa 55–206) of HIV-1 Nef is sufﬁcient for binding to eEF1A. Upper left panel, Schematic diagram of
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viaits C-terminalregion (aa 55–206). Thebinding of eEF1Apresent in lysatesof MDMs was measuredin GST pull-downassaysusingWT and mutated GST–Nefconstructs.
Input corresponds to 10% of the material used for pull-down. Results are representative of two independent experiments
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Cell Death and Diseasewhether Nef can prevent cytochrome c release in the
cytoplasm. We found that most of the cytochrome c was
detected in the mitochondrial fraction from normal MDMs,
whereas the majority of the cytochrome c in BFA-treated
MDMs was detected in the cytosolic fraction (Figure 5e). In
Nef-treated MDMs, most of the cytochrome c was detected
in the mitochondrial fractions, even after BFA stimulation,
which suggests that mitochondrial cytochrome c release
is blocked by Nef treatment (Figure 5e). The release of
mitochondrial cytochrome c into the cytoplasm in BFA-
stimulated MDMs was inhibited mostly at high Nef concen-
trations (Figure 5f).
AsshowninFigure5g,cleavage of45-kDa procaspase-9to
a 35-kDa fragment in MDMs treated with BFA was blocked by
Nef, but not by inactivated boiled Nef, conﬁrming that BFA-
induced apoptosis activates caspase-9 and that it can be
inhibitedbyNef.Theprocessingofcaspase-9inducedbyBFA
in Nef-treated MDMs was inhibited in a dose-dependent
manner (Figure 5h), indicating that Nef may function by
preventing the activation of caspase-9 via decreased release
of mitochondrial cytochrome c. As shown in Figure 5i,
pretreatment with rNef did not inhibit the processing of
caspase-3 and caspase-9 induced by TM or TG.
eEF1A/Nef complexes contain tRNAs and block stress-
induced apoptosis in MDMs through tRNA binding to
cytochrome c. As both eEF1A and HIV-1 Nef bind to tRNAs
preferentially,
32 we speciﬁcally assessed the presence of
several tRNAs in the rNef/eEF1A complexes in MDMs
treated with rNef. MDMs treated with rNef were lysed and
the presence of tRNAs in the immunoprecipitated eEF1A/
rNef complexes analyzed using RT-PCR. We detected the
presence of all tested tRNAs, namely tRNAMet, tRNAPhe,
tRNATry and tRNALys in the eEF1A/rNef complexes in
MDMs (Figures 6a–c). The DDCt values were determined
separately for untreated cells and averaged around 1
(Supplementary Figure 2).
The binding of tRNAs to cytochrome c was recently
reported to inhibit caspase-9 activation. Therefore, we
hypothesized that the enhanced nuclear-cytoplasmic trans-
port of eEF1A/rNef/tRNA complexes mediated by Exp-t
might result in higher levels of cytosolic tRNAs, which
could target cytochrome c released in BFA-treated MDMs.
Cytoplasmic extracts of MDMs treated with increasing
amounts of rNef were tested for the presence of tRNAs
complexed with immunoprecipitated eEF1A and cytochrome
c. We observed that tRNA binds to eEF1A in the cytosol of
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Figure 3 Nuclear-cytoplasmic relocalization of eEF1A/rNef complexes occurs in MDMs treated with rNef and depends on Exp-t. (a) Kinetics of eEF1A/rNef/Exp-t
complexes in nuclear and cytoplasmic compartments of MDMs. Nuclear and cytoplasmic extracts of MDMs treated with rNef (100ng/ml) were prepared and the eEF1A/rNef,
rNef/Exp-t and eEF1A/Exp-t interactions assessed in both cellular compartments up to 12h post-treatment using co-immunoprecipitation and western blotting. Similarly,
nuclear and cytoplasmic extracts of untreated MDMs (Mock) were prepared and tested for the expression of eEF-1A. b-Actin and TBP were used as loading controls.
Results are representative of three independent experiments. (b) Using wild-type GST–Nef constructs, the binding of Exp-t present in MDM lysates was assessed in GST
pull-down assays. Input corresponds to 10% of the material used for pull-down. Results are representative of two independent experiments. (c) eEF1A interacts with Exp-t in
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arbitrarily established at 1)
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Cell Death and DiseaseBFA-treated MDMs in a Nef-dependent manner (Figure 6d).
Similar results were obtained for the binding of tRNA to
cytochrome c (Figure 6e), indicating that Nef treatment
of BFA-stimulated MDMs favors the formation of tRNA/
cytochrome c complexes in the cytoplasm. Cytoplasmic
extracts of BFA-stimulated MDMs treated with rNef, in the
absence or presence of Exp-t siRNA, Exp-1 siRNA or Exp-5
siRNA, were analyzed for the presence of tRNA binding
cytochrome c. Knockdown of Exp-t, but not Exp-1 or Exp-5,
decreased the amount of tRNA bound to cytochrome c,
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Figure 4 rNef-mediated inhibition of BFA-induced apoptosis in MDMs parallels cytoplasmic accumulation of eEF1A and is dependent on Exp-t. (a) rNef prevents BFA-
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Cell Death and Diseaseas well as eEF1A, in BFA-stimulated MDMs treated with Nef
(Figures 6f and g).
Discussion
We observed a direct interaction between HIV-1 Nef and
eEF1A. Nuclear-cytoplasmic relocalization of rNef/eEF1A/
tRNA complexes prevented stress-induced apoptosis of
MDMs treated with BFA through decreased release of
mitochondrial cytochrome c, enhanced tRNA binding to
released cytosolic cytochrome c and increased cytoplasmic
levels of eEF1A, ultimately resulting in decreased caspase
activation (Figure 7). Our results indicate that the HIV-1 Nef
protein enhances resistance to stress-induced apoptosis in
MDMs through the nuclear-cytoplasmic relocalization of rNef/
eEF1A/tRNA complexes.
Our results show that nuclear-cytoplasmic transport of
eEF1A/Exp-t/tRNA complexes occurs in MDMs treated with
rNef. Although the role of eEF1A in tRNA transport has been
reported, this is the ﬁrst time that a viral protein such as Nef
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Cell Death and Diseasehasbeen showntobeactivelyinvolved insuchaprocess.The
presence of large amounts of eEF1A in the nucleus of MDMs
conﬁrms previous results indicating that eEF1A is localized in
both the cytoplasm and nucleus of cells. We also observed
that the nuclear-cytoplasmic distribution of eEF1A/rNef
complexes included the presence of RNA (Figures 6a–c).
Both proteins most probably bind to each other in a RNA-
independent manner. First, we observed the interaction
between Nef and eEF1A in a puriﬁed system (Figure 2a).
Second, supportive experimental evidence comes from
crosslinking studies between rabbit EF-1a.GTP and aminoa-
cyl-tRNA that indicate contact sites corresponding to residues
270–275, 345–355 and 375, sites that are in contact with the
RNA in the ternary complex crystal.
33 Finally, the N-terminal
Arg-rich region of HIV-1 Nef (aa 1–22) binds to RNA in vitro.
32
As the Nef fragment encoding amino acids 55 to 206 is
sufﬁcient for binding to the N-terminal extremity of eEF1A
(Figure 2b), it is highly unlikely that the Nef interaction with
eEF1A requires the presence of RNA.
We hypothesized that tRNA is the most likely candidate to
be present in the Nef–eEF1A complex because eEF1A binds
to aminoacyl-tRNA during translation and Nef has been
shown to bind to tRNAs and promote the annealing of primer
tRNA to viral genomic RNA. In addition, Exp-t, rather than
Exp-5, has a critical role in this process, which is in agreement
with a critical role of Exp-t in the selection and transport of
mature tRNAs from the nucleus to the cytoplasm.
Nef has been reported to prevent both Fas and TNF
receptor-mediated deaths in HIV-infected T cells via interac-
tion with ASK-1, thereby blocking the extrinsic apoptosis
pathway. Nef inhibits ASK-1, caspase-3 and caspase-8
activation, resulting in the blockade of apoptosis in HIV-
infected cells. Nef has also been shown to block the intrinsic
apoptosis pathway via the inhibition of the proapoptotic
protein Bad.
34 Our data highlight a new molecular mechanism
elicitedbytheHIV-1Nefproteintoblocktheintrinsicapoptosis
pathway in Nef-expressing cells, such as HIV-1-infected
MDMs. The HIV-1 Nef protein, through the nuclear-cytoplas-
mic relocalization of rNef/eEF1A/tRNA complexes, could
participate in preventing stress-mediated effects at several
levels. First, the decreased cytochrome c release is probably
due to cytoplasmic accumulation of eEF1A that stabilizes
actin ﬁlaments and potentially could block the BFA-induced
disruption of the organization of the microtubule and actin
cytoskeleton. Second, the tRNAs could be speciﬁcally
delivered by the eEF1A/Nef/tRNA complexes to cytosolic
cytochrome c, thereby preventing cytochrome c interaction
with Apaf-1 and blocking caspase activation and apoptosis.
Third, the eEF1A protein could be delivered by the eEF1A/
Nef/tRNA complexes in the cytoplasm to participate in
cytoskeleton rearrangement aimed to eliminate unfolded
proteins produced during stress events.
35–37 Finally, eEF1A
has been reported to activate Akt, the protein kinase B
reported by numerous studies to favor resistance to apopto-
sis.
11 In order to determine the scope of eEF1A-mediated
protection, we assayed eEF1A antiapoptotic activity in
response to ER-stress agents, BFA, TM and TG. BFA
reversibly blocks protein transport between the ER and Golgi,
whereas TM blocks the synthesis of all N-linked glycoproteins
and TG inhibits the ER Ca
2þ-ATPase family of calcium pumps.
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Figure 5 rNef-mediated cytoplasmic accumulation of eEF1A in BFA-treated MDMs inhibits caspase activation and decreases the cytoplasmic release of cytochrome c.
(a)Inhibitionofcaspase-3activationinBFA-stimulatedMDMstreatedwithrNef(1000ng/ml).(b)Inhibitionofcaspase-3activationinBFA-stimulatedMDMstreatedwithrNefis
dose-dependent and positively correlates with cytoplasmic accumulation of eEF1A. (c) Knockdown of Exp-1 and Exp-5 proteins by siRNA in MDMs. MDM cultures were
transfected with scrambled control, Exp-1 siRNA or Exp-5 siRNA. Total cellular extracts were prepared 48h post-transfection. Protein expression was analyzed by western
blot. b-Actin was used as a loading control. (d) Inhibition of caspase-3 activation in BFA-stimulated MDMs treated with rNef is dependent on Exp-t. (e) Mitochondrial
cytochrome c release in BFA-treated MDMs is blocked by rNef. (f) Mitochondrial cytochrome c release in BFA-treated MDMs is blocked by rNef in a dose-dependent manner
andpositivelycorrelateswith cytoplasmicaccumulationofeEF1A.(g)Inhibitionofcaspase-9activationinBFA-stimulatedMDMstreatedwithrNef(1000ng/ml).Proteinlevels
of caspase-9 were quantiﬁed by densitometry using ImageJ 1.40 software (the level of caspase-9 in mock cells was arbitrarily established at 1). (h) Inhibition of caspase-9
activation in BFA-stimulated MDMs treatedwith rNef is dose-dependent. Protein levels of caspase-9 were quantiﬁedby densitometry using ImageJ1.40 software (thelevel of
caspase-9in mockcells was arbitrarilyestablishedat 1). (i) Inhibitionof caspaseactivation inBFA-stimulatedMDMs treatedwith rNef, butneitherin TM-stimulated MDMs nor
inTG-stimulatedMDMstreatedwithrNef.Leftpanel,TimecourseofcaspaseactivationinBFA-stimulatedMDMs,TM-stimulatedMDMs,orTG-stimulatedMDMs.Rightpanel,
Inhibition of caspase activation in BFA-stimulated MDMs treated with rNef, but neither in TM-stimulated MDMs nor in TG-stimulated MDMs treated with rNef. MDM cultures
were treated with BFA (10mg/ml), TM (10mg/ml) or TG (10mg/ml) for 12h in the presence of rNef (1mg/ml), and caspase-3 and caspase-9 activation was measured in total
cellular lysates. Results are representative of data obtained in three independent experiments
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Cell Death and DiseaseOur results indicate that Nef speciﬁcally blocks apoptosis
inducedbytheER-stressagentBFA,indicatingthatincreased
cytoplasmic relocalization of eEF1A by HIV-1 Nef may alleviate
the inhibition of protein transport between the ER and Golgi
observed in BFA-treated cells. In addition, Nef could favor an
homeostatic control of UPR and of oxidative stress observed
during the acute phase of HIV infection and subsequently fuel
the progression of the disease toward a chronic infection with
the formation of cellular reservoirs of the virus.
Taken together, the results indicate that cytoplasmic
relocalization of the eEF1A/tRNAs complexes by HIV-1 Nef
could ultimately favor the survival of the cell under stress,
thereby allowing optimal viral replication. This event may
participate in the formation and maintenance of viral reser-
voirs in HIV-infected persons.
Materials and Methods
Cell culture. Primary human MDMs were prepared from the peripheral blood of
healthy donors and cultured in RPMI medium supplemented with 10% (v/v) pooled
AB human serum (Sigma, Munich, Germany) as described previously.
38 PBLs were
cultivated in RPMI medium supplemented with 10% (v/v) fetal bovine serum (FBS). Vero
cells, MRC5 cells and promonocytic U937 cells were obtained from the American Tissue
Cell Culture Collection (ATCC, Manassas, VA, USA). The cell lines were cultivated in
RPMI 1640 supplemented with 10% FBS, 1% glutamine and 1% penicillin/streptomycin.
Recombinant Nef treatment. MDMs (5 10
6 cells) were treated with
recombinant myristoylated Nef protein (rNef) from Jena Bioscience (Jena, Germany).
Cell pellets were collected at various times after treatment, washed extensively and
either lysed for western blot analysis or ﬁxed with 3% paraformaldehyde in PBS for
30min for ﬂow cytometric analysis. The bacterially expressed GST–Nef(WT), GST–
Nef(1–60) and GST–Nef(55–206) were puriﬁed and cleaved with thrombin (cat. no.
27-0846-01; GE Healthcare, Little Chalfont, Buckinghamshire, UK) according to the
instructions provided by the manufacturer. SDS-Tricine polyacrylamide gel
electrophoresis (PAGE) and Coomassie staining was done to visualize the thrombin
cleaved products of HIV-1 Nef wild-type and mutants.
Isolation of nuclear and cytoplasmic extracts. Nuclear and
cytoplasmic extracts were isolated as described previously.
38 Protein concentra-
tions in the nuclear and cytoplasmic extracts were determined by the Bradford
method using a BioPhotometer (Eppendorf, Hamburg, Germany).
Preparation of cytosolic and mitochondrial fractions. Cytosolic
and mitochondrial fractions were prepared using the cell fractionation kit-standard
(#MS861, Mitosciences, Eugene, OR, USA). The coxIV (Cell Signaling Technology,
Danvers, MA, USA) antibody was used as a mitochondrial loading control.
Immunoprecipitation. Vero cells, MRC5 cells, U937 cells, PBLs or primary
MDMs were left untreated or treated with rNef for different periods of time. Cell
lysates were precleared by adding 50ml of Protein-G Plus/Protein A-Agarose
(Calbiochem-Novabiochem, Bad Soden, Germany) for 1h at 41C. The cleared
supernatants were removed, combined with 5mg anti-Nef or anti-EF1A antibodies
(Chemicon, Upstate, Billerica, MA, USA), and incubated overnight at 41C.
Immune complexes were washed in the presence of protease inhibitors, the
bound proteins eluted with sample buffer and the proteins run on a 10% SDS-
PAGE gel. SDS-PAGE and western blot analysis were performed according to
standard procedures. b-Actin and TATA binding protein (TBP; Sigma, St. Louis,
MO, USA) were used as cytoplasmic or nuclear loading controls, respectively.
Western blots were developed using the ECL detection kit (Amersham Pharmacia
Biotech, Little Chalfont, Buckinghamshire, UK).
Far-western identiﬁcation of Nef protein interactions. Protein–
protein interaction screening was performed on hE 1 high-density protein
expression cDNA libraries with rNef protein, which was expressed by the
prokaryotic expression vector pET-32 (Novagen, Madison, WI, USA) according to
previously published protocols.
Plasmids and construction of expression vectors. The pcDNA6-
based expression vectors for HIV-1 Nef and eEF1A have been described
elsewhere.
39 Deletion constructs were generated by standard PCR and cloning
procedures. HIV-1 Nef and EF1A constructs were veriﬁed by DNA sequencing.
eEF1A/Nef interactions were detected in vivo by transient co-transfection of
GAL4–Nef and VP16–eEF1A in the context of a mammalian two-hybrid system
(CheckMate, Promega, Madison, WI, USA). Sequence authenticity was conﬁrmed
by cDNA cycle sequencing.
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Figure 6 rNef-mediated cytoplasmic accumulation of eEF1A in BFA-treated MDMs parallels tRNA binding to cytochrome c.( a) Direct detection of tRNAs in rNef/eEF1A
complexes inMDMs treated with rNef. Lysates from MDMs treated with rNef (100ng/ml) for 3h or left untreated (Mock) were prepared, immunoprecipitated with anti-eEF1A and
anti-Nefantibodies,andtRNALysintheeEF1A/rNefcomplexesampliﬁedbyRT-PCR.Lysateswerealsoimmunoprecipitatedwithisotypecontrolantibody.ThepresenceofHIV-1
Nef protein in the immune complex was determined by western blot. As an internal control, lysates from MDMs treated with rNef (100ng/ml) for 3h were prepared, treated with
RNAse A (10mg/ml) for 30min, immunoprecipitated with an anti-eEF1A antibody, and tRNALys in the eEF1A/Nef complexes was ampliﬁed by RT-PCR. (b and c)M D M sw e r e
treatedwithrNef(100ng/ml);thelysateswereimmunoprecipitatedwithananti-NefAb(b)oranti-eEF1AAb(c)andthepresenceoftRNAMet,tRNALys,tRNATryandtRNAPhein
the Nef/eEF1A complex determined by qRT-PCR. (d and e) MDMs were treated with BFA for 12h in the presence or absence of rNef (0–1500ng/ml); the lysates were
immunoprecipitated with an anti-eEF1A Ab (d) or anti-cytochrome c Ab (e), and the presence of tRNAMet, tRNALys, tRNATry, and tRNAPhe was determined by qRT-PCR.
(f and g) The presence of tRNAs associated with eEF1A and cytochrome c in BFA-stimulated MDMs treated with rNef is dependent on Exp-t. MDM cultures were transfected
withscrambledcontrolsiRNA, Exp-tsiRNA,Exp-1 siRNA orExp-5siRNA. Cytoplasmicextractsof MDMstreatedwith BFA (10mg/ml) for12h intheabsenceorpresenceofrNef
(1000ng/ml)wereprepared48hpost-transfection,immunoprecipitatedwithananti-eEF1AAb(f)oran ti -c yt oc hr om ecAb(g),andthepresenceoftRNALys,tRNAMet,tRNAPhe,
and tRNATry binding to eEF1A and cytochrome c was determined using qRT-PCR. Results representative of three independent experiments are shown; * Po 0.05
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Cell Death and DiseaseHIV-1 Nef wild type, N terminus (1–60) or C terminus (55–206) was cloned into
pGEX-4T-1expressionvector.Forproteinpuriﬁcationpurposes,eachconstructwas
transformed into bacteria (BL21DE from Novagen). A single colony was inoculated
in 5ml LB broth plus 50mg/ml ampicillin at 371C in a shaker overnight. A 1ml
aliquot of the overnight bacterial culture was used to inoculate 300ml LB broth plus
50mg/ml ampicillin and grown for 2.5h at 371C in a shaker (until OD600¼0.5).
IPTG was added at a ﬁnal concentration of 0.1mM and the culture grown for an
additional 3h at 371C in the shaker. Bacteria were pelleted, washed with ice-cold
TBS, and lysed in bacterial protein extraction reagents (Pierce, Rockford, IL, USA).
eEF1A and mutants were constructed and expressed in the bacteria as described
previously.
25
Transfection assay. To carry out transient transfections, the DNA
concentration was kept constant in the different samples by using the
corresponding empty vector. A total of 5 10
6 cells were transfected with
5–10mg total plasmid DNA, which included the ﬁreﬂy luciferase-expressing vector
using the DEAE-dextran procedure. Luciferase activity in cell lysates was
measured 48h post-transfection using a luminometer (TD-20/20, Promega).
Luciferase expression was normalized with respect to protein concentration using
the Detergent-Compatible Protein Assay (Bio-Rad, Munich, Germany). All
transfections were performed in triplicate.
Pull-down assays. Fragments of the cDNA encoding HIV-189.6 Nef were
produced using convenient restriction enzymes and PCR methods and then
cloned into the GST fusion vector pGEX-4T-1 (Amersham Biosciences,
Little Chalfont, Buckinghamshire, UK). The GST constructs were transformed
into the E. coli strain BL21 (Stratagene, La Jolla, CA, USA), and the GST fusion
proteins were puriﬁed according to the manufacturer’s instructions. For pull-down
assays, 20mg of the GST–Nef proteins (NefWT, Nef(1–60), Nef(55–206)) kindly
provided by Dr. Fackler (University of Heidelberg, Germany) were incubated
overnight at 41C with 1500mg of MDM lysate. The suspension was then washed
three times in PBS, denaturized and subsequently separated by SDS-PAGE
before autoradiography.
RNA interference. MDM cultures (0.5 10
6 cells) were transfected with a
scrambled control, Exp-t siRNA, Exp-1 siRNA or Exp-5 siRNA duplex (Santa-Cruz
Biotechnology, Santa Cruz, CA, USA) using Lipofectamine RNAiMAX (Invitrogen,
Carlsbad, CA, USA). MDMs were treated with rNef 48 h post-transfection, and
eEF1A, rNef, Exp-t, Exp-1 and Exp-5 protein expression and MDM apoptosis
analyzed by western blot and annexin-V (Invitrogen) assay, respectively.
Transfection efﬁciency was monitored using a ﬂuorescein-conjugated scrambled
control duplex, exceeding 80% in MDMs.
tRNA interaction with cytochrome c, eEF1A or Nef. To examine the
tRNA/cytochrome c interaction in vivo, MDMs transfected with Exp-t siRNA, Exp-1
siRNA, Exp-5 siRNA, or scramble siRNA for 48h before treatment with rNef were
harvested and washed twice with ice-cold PBS. The cytoplasmic extracts were
immunoprecipitated with anti-cytochrome c antibody (Santa-Cruz Biotechnology)
at 41C overnight followed by incubation with protein-G agarose beads for an
additional 2h. The beads were washed and resuspended in 200ml in RNA elusion
buffer (50mM Tris, 100mM NaCl, 10mM EDTA, 0.1% SDS) at 651C for 10min.
RNA was extracted (RNeasy kit, Qiagen, Hilden, Germany) and cDNA synthesized
using a cDNA synthesis kit (Invitrogen).
The sequence of the primers (Eurogentec, Lie `ge, Belgium) used in RT-PCR
ampliﬁcation were as follows:
tRNA Met forward 50-CTGGGCCCATAACCCAGAG-30
tRNA Met reverse 50-TAGCAGAGGATGGTTTCGAT-30
tRNA Tryp forward 50-GGCTCGTTGGTCTAGGGGTA-30
tRNA Tryp reverse 50-GATTTGAACCCGGGACCT-30
tRNA Phe forward 50-CCTCCTCAAAGCAATACACTGA-30
tRNA Phe reverse 50-GGTGATGTGAGCCCGTCTAA-30
tRNA Lys forward 50-ATAGCTCAGTCGGTAGAGCATCA-30
tRNA Lys reverse 50-ACAGGGACTTGAACCCTGGAC-30
The tRNAs associated with eEF1A and rNef were detected after immunoprecipi-
tation with an anti-eEF1A or anti-Nef antibody, followed by RT-PCR ampliﬁcation as
describedabove. Ctvalues were analyzed using the DDCtmethod.
40DCtwas calculated
by normalization to the isotype control, and DDCt values were calculated by normalizing
to the Ct values of the untreated sample. The DDCt values were also determined
separately for untreated cells and averaged around 1 (Supplementary Figure 2).
Detection of apoptosis. The detection of apoptosis by annexin-V-propidium
iodide assay (Invitrogen) and TUNEL assay (AbD Serotec, Oxford, UK) was
performed as previously described.
29 For ER-stress agents, an appropriate dose
was selected from a range of concentrations tested. BFA (Sigma, USA), TG
(Sigma, USA) and TM (Sigma, USA) were used at 10mg/ml.
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Figure 7 Potential inhibitory effect of the eEF1A/rNef/tRNA complex on the intrinsic apoptotic pathway in BFA-treated MDMs. HIV-1 Nef protein favors translocation and
accumulation of eEF1A from nucleus toward to the cytoplasm of the cell. tRNA is present in the Nef/eEF1A complex, which is exported by exportin-t and buffers the
cytochrome c released under oxidative stress conditions. At the same time the Nef/eEF1A complex inhibits the caspase activation. Further, eEF1A could stabilize the
microtubules and give relief to the cell to survive under stress conditions. BFA, brefeldin-A; Expt, exportin-t
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Cell Death and DiseaseCaspase activity. Caspase-9 and caspase-3 activity was measured by
western blotting as described previously.
31 Where speciﬁed, protein levels were
quantiﬁed by densitometry using ImageJ 1.40 software (National Institute of
Health, Bethesda, MD, USA).
Statistical analysis. Statistical analyses were performed using the analysis of
variance test, and differences were considered signiﬁcant at a value of *Po0.05,
**Po0.01 and ***Po0.001. Microsoft Excel was used to construct the plots.
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